ArticleCureus2026
Circulating miRNA-21 and miRNA-155 Expression in Adult Patients With Bronchial Asthma and Its Association With Lung Function.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesMicroRNAs (miRNAs) regulate post-transcriptional gene expression and have emerged as important contributors to the pathogenesis of asthma, as well as potential biomarker candidates. In this study, we evaluated the serum miRNA-21 and miRNA-155 expression in bronchial asthma and its association with lung function and inflammatory markers.
methodsIn this pilot case-control study, a total of 72 participants were enrolled, including 36 adults with spirometry-confirmed asthma and 36 healthy controls recruited from hospital staff and attendants without respiratory symptoms or history of allergic disease. Spirometry was also performed in controls to exclude occult airflow limitation. A predefined exploratory hypothesis was that circulating miRNA-21 and miRNA-155 expression would differ between asthma and controls and may correlate with inflammatory biomarkers and lung function. Serum miRNA-21 and miRNA-155 expression was quantified by quantitative real-time polymerase chain reaction. Between-group comparisons were performed using the Mann-Whitney U test, and correlations with serum IgE, absolute eosinophil count (AEC), forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were examined using Spearman's rank correlation coefficient.
resultsmiRNA-21 expression was significantly higher in patients compared to controls with median values of 0.191 (IQR 0.114-0.312) vs 0.054 (IQR 0.027-0.195), P=0.006. In contrast, miRNA-155 expression did not differ significantly between the groups (median 0.159 (IQR 0.068-0.363) vs 0.220 (IQR 0.107-0.338), P=0.240). Among correlation analyses, only miRNA-155 showed a significant positive correlation with serum IgE (Spearman's ρ=0.654, P<0.001) and no significant association of miRNA-21 with the IgE level. Neither miRNA correlated significantly with AEC, FEV1 or FVC. INTERPRETATION &
conclusionsSerum miRNA-21 was significantly upregulated in bronchial asthma, supporting its possible association with asthma-related immune dysregulation. Although miRNA-155 was not differentially expressed between groups, its positive association with serum IgE suggests a possible relationship with atopic inflammatory pathways. These findings suggest that circulating miRNAs may reflect asthma-related inflammatory activity; however, their clinical biomarker utility requires further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.